Hillier et al., Generation and Analysis of 280,000 Humans Expressed Sequence Tags, Genome Research, vol. 6, pp. 807-828, 1996* |
Sambrook et al., Molecular Cloning vol. 3, pp. 16.68-16.81, 1989.* |
Harris et al., Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect, Journl of the American Society of Nephrology, vol. 6, No. 4, pp. 1125-1133, 1995.* |
Ahn et al., The structural and functional diversity of dystrophin, Nature Genetics, vol. 3, pp. 284-291, 1993.* |
Cawthon et al.; cDNA Sequence and Genomic Structure of EV12B, a Gene Lying within an Intron of the Neurofibromatosis Type 1 Gene, vol. 9, pp. 446-460, 1991.* |
Genbank Accession No. AA075632, Dec. 1997.* |
Genbank Accession No. AA640762, Oct. 1997.* |
Bookman et al., “Biological therapy of ovarian cancer: Current directions,” Seminars in Oncology, 25(3):381-396. (1998). |
Gillespie et al., “Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue,” British Journal of Cancer, 78(6):816-821, Sep., 1998. |
Heller et al., “Discovery and analysis of inflammatory disease-related genes using cDNA microarrays,” Proc. Natl. Acad. Sci. USA 94:2150-2155, Mar., 1997. |
Ishikawa et al., “Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins in vitro,” DNA Res., 5:169-176, 1998. |
Jin et al., “Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MAD1,” Cell 93:81-91, Apr. 3, 1998. |
Köhler et al., “Immotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotype Antibody ACA125—Results of the Phase LB Study,” Gebrutshilfe und Fraenheilkunde, 58(4):180-186, Apr. 1998, + (English Abstract). |
Ma et al., “Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses,” Journal of Pharmaceutical Sciences, 87(11):1375-1378, Nov. 1998. |
Peoples et al., “Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides,” Annals of Surgical Oncology, 5(8):743-750, Dec., 1998. |
Schena et al., “Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes,” Proc. Natl. Acad. Sci., 93:10614-10619, Oct., 1996. |
Hovig, E. et al., “CA 125: The End of the Beginning,” Tumor Biology 22: 345-347, 2001. |
O'Brien, T.J. et al., “The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure,” Tumor Biology 23: 154-169, 2002. |
O'Brien, T.J. et al., “The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences,” Tumor Biology 22: 348-366, 2001. |
Schummer, M. et al., “Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas,” Gene 238: 375-385, 1999. |
Whitehouse, C. et al., “NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube,” Eur. J. Biochem. 269: 538-545, 2002. |
Yin and Lloyd, “Molecular Cloning of the CA125 Ovarian Cancer Antigen. Identification as a new mucin, MUC16,” Journal of Biological Chemistry 276(29): 27371-27375, Jul. 20, 2001. |
Yin, B.W.T. et al., “Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene,” International Journal of Cancer 98: 737-740, 2002. |